Clinical Scorecard: Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda
At a Glance
| Category | Detail |
|---|---|
| Condition | Sickle Cell Disease (SCD) |
| Key Mechanisms | Gene therapy aimed at correcting genetic defects causing SCD. |
| Target Population | Patients with Sickle Cell Disease in Uganda. |
| Care Setting | Low-income healthcare settings. |
Key Highlights
- Gene therapy could be cost-effective in Uganda if prices are reduced.
- Lifetime standard-of-care cost for SCD in Uganda is estimated at $21,877.
- Casgevy is more viable than Lyfgenia when adjusted for local costs.
- Affordability hinges on pricing and societal benefits.
- The study provides a framework for policymakers to enhance access to gene therapy.
Guideline-Based Recommendations
Diagnosis
- Utilize local treatment cost data to assess cost-effectiveness of therapies.
Management
- Consider gene therapy options like Casgevy and Lyfgenia based on local affordability.
Monitoring & Follow-up
- Evaluate health gains and societal benefits post-therapy implementation.
Risks
- High list prices may limit access to effective treatments.
Patient & Prescribing Data
Individuals diagnosed with Sickle Cell Disease in Uganda.
Cost-effectiveness of gene therapies is contingent on significant price reductions.
Clinical Best Practices
- Adapt high-income cost-effectiveness models to local contexts.
- Factor in societal benefits when evaluating treatment options.
- Engage policymakers to support equitable access to therapies.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
